However, being a direct target of miR-448, PTPN2 expression was reduced in PBMC and CSF from MS patients [41], whereas we observed a small increase in stimulated CD4+ T cells from MS patients (log2 fold change = 0.85). Here, PTPN2 is linked to myeloid sarcoma.